This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Astrazeneca Ab, Mitsubishi Tanabe Pharma Corporation. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,534 
2 out of 263 
Years Active: 2024-2025
Title: Henrik Gradén: Innovator in Pharmaceutical Compounds
Introduction
Henrik Gradén is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target the NLRP3 inflammasome.
Latest Patents
Henrik Gradén holds 1 patent related to "Compounds and their use." This patent generally pertains to compounds of Formula (I) and their pharmaceutically acceptable salts. These compounds are designed to inhibit NLRP3 inflammasome activity, making them potentially useful as therapeutic agents. The patent also discusses the application of these compounds in treating or preventing diseases associated with the NLRP3 inflammasome.
Career Highlights
Throughout his career, Henrik has worked with prominent companies in the pharmaceutical industry, including AstraZeneca AB and Mitsubishi Tanabe Pharma Corporation. His experience in these organizations has allowed him to contribute to significant advancements in drug development.
Collaborations
Henrik has collaborated with several professionals in his field, including Lars Anders Mikael Johansson and Giulia Bergonzini. These collaborations have likely enhanced his research and development efforts.
Conclusion
Henrik Gradén's work in developing innovative pharmaceutical compounds demonstrates his commitment to advancing medical science. His contributions are valuable in the ongoing fight against diseases linked to the NLRP3 inflammasome.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile